Adagio Medical Holdings, Inc. (ADGM) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Company: Adagio Medical Holdings, Inc. (Successor to Legacy Adagio Medical, Inc.)
Reporting Period: Three months ended March 31, 2025
Business Overview: A medical technology company developing ablation technologies (ULTC and PFCA platforms) for cardiac arrhythmias, specifically ventricular tachycardia (VT). The company operates as a single reportable segment.
Recent Corporate Action: The company completed a business combination with ARYA Sciences Acquisition Corp IV on July 31, 2024. The Q1 2025 results reflect the "Successor" period, while Q1 2024 reflects the "Predecessor" period.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 (Successor) | Q1 2024 (Predecessor) |
|---|---|---|
| Revenue | $0 | $26 |
| Net Loss | $(7,713) | $(8,018) |
| Loss Per Share (Basic/Diluted) | $(0.50) / $(0.51) | $(10.28) |
| Operating Cash Flow | $(7,211) | $(6,739) |
| Cash and Cash Equivalents (End of Period) | $12,963 | $4,083 |
| Total Debt (Convertible Notes) | $17,652 | N/A (Converted/Refinanced) |
| Accumulated Deficit | $(78,256) | $(143,223) |
Material Changes vs. Prior Period
- Revenue: Revenue was nil in Q1 2025 compared to $26,000 in Q1 2024. The decrease was due to an inventory buyback in Europe offsetting gross sales, coinciding with a pause in commercial activity.
- Operating Expenses: Total operating expenses decreased by 16% to $7.4 million.
- R&D: Increased 5% to $3.7 million, driven by higher clinical trial and product development costs, partially offset by reduced QA/operations costs.
- SG&A: Decreased 28% to $3.5 million, primarily due to lower payroll and personnel expenses following a corporate prioritization initiative.
- Other Income/Expense: Total other expense was $(316) thousand in Q1 2025, a significant shift from $797 thousand income in Q1 2024. This was driven by a reduction in the fair value gain on convertible notes (from $1.7M gain to $0.2M gain) and increased interest expense.
- Stock-Based Compensation: Increased to $218,000 in Q1 2025 from $110,000 in Q1 2024 due to new equity plans adopted post-merger.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that current cash resources ($13.0 million) are insufficient to fund operations for the next 12 months. This raises substantial doubt about the company's ability to continue as a going concern. Mitigation strategies include seeking equity/debt financing, pursuing FDA approval, and cost-cutting.
- Corporate Prioritization: In February 2025, the company implemented an initiative to focus resources on the FULCRUM-VT clinical trial and product design optimization, resulting in one-time expenses and reduced headcount.
- Regulatory Outlook: The vCLAS Cryoablation System has CE Mark approval in Europe. The FULCRUM-VT pivotal trial in the U.S. is enrolling, with completion anticipated in H2 2025 to support FDA approval. The FDA granted Breakthrough Device Designation for vCLAS in April 2025.
- Risks: Key risks include the inability to raise additional capital, delays in clinical trials, regulatory hurdles, and potential impacts of international trade tariffs on supply chain costs.
- Unusual Items: The financial statements reflect a "Successor" vs. "Predecessor" accounting treatment due to the July 2024 business combination, limiting direct comparability of balance sheet items and equity structure.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and terms of any new financing arrangements to address the "substantial doubt" regarding going concern status.
- Clinical Trial Progress: Monitor enrollment rates and interim data for the FULCRUM-VT trial, which is critical for U.S. commercialization.
- Debt Obligations: Review the terms of the $17.7 million Convertible Securities Notes (13% interest, convertible at $10.00/share) and potential dilution upon conversion.
- Cost Reduction Sustainability: Assess whether the SG&A reductions from the corporate prioritization initiative are sustainable without impacting R&D velocity.
- European Commercial Activity: Confirm the status of the commercial pause in Europe and the timeline for resuming sales.